Prospective and retrospective studies of mild cognitive impairment : Alzheimer disease and senile tauopathy
轻度认知障碍的前瞻性和回顾性研究:阿尔茨海默病和老年性tau蛋白病
基本信息
- 批准号:14570626
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Mild cognitive impairment (MCI) is defined as the intermediate state between normal cognition and dementia and highlighted as the main target for preventive scheme against cognitive decline in the elderly.We screened clinical records of 1,120 serial autopsy cases from Tokyo Metropolitan Brain Bank for Aging Research in these five years. The cases equivalent to MCI were retrospectively selected by two professional neurologists independently, on the following criteria: 1.the description of memory impairment incurring problems for medical care,2.no definite description of dementia, and 3.Clinical Dementia Rating 0.5.One hundred and seventy one cases were pulled out as MCI equivalents. The background pathology of these cases consisted of 25 cases mainly presenting with Alzheimer disease (AD)-type pathology,23 cases of senile tauopathy, comprising dementia with grain or neuforibrillary tangle-predominant form of dementia-type changes and others.With this result, we have established the crit … More ical path for MCI. The initial screening consists of neurological examination, Mini-Mental State Examination and CTscan. The secondary screening includes volumetric MRI, statistical SPECT, the Rivermead Behavioral Memory Test (RBMT) and electroencephalography (EEG). Those patients who fulfill the criteria of MCI are recruited to the prospective study with informed consent. The advanced examination includes biological marker of cerebrospinal fluid (tau, phosphorylated tau and Abeta), apoE phenotyping, WAIS-R, WMS-R and PET scans. MCI cases with possible early AD or senile tauopathy are recruited to medical control by acetylcholine esterase inhibitor.We have run this critical path this year. Tentative summaries are as follows: 1.MCI includes many cases in addition to AD. 2.Appropriate medical intervention could prevent and, in some cases, reverse the progression of cognitive decline. 3.Early intervention is quite useful for the preservation of the quality of life.Further accumulation of the cases are now on going. Less
轻度认知功能障碍(MCI)是介于正常认知和痴呆之间的中间状态,是老年人认知功能减退预防的主要目标。本研究筛选了东京都老龄化研究脑库近5年来1,120例连续尸检病例的临床记录。由两名神经科医师根据以下标准独立回顾性选择符合MCI的病例:1.描述记忆障碍导致医疗护理问题,2.没有明确的痴呆描述,3.临床痴呆评分0.5。这些病例的背景病理包括25例主要表现为阿尔茨海默病(AD)型病理的病例,23例老年性tau蛋白病,包括痴呆伴颗粒或神经纤维缠结为主形式的痴呆型改变和其他。 ...更多信息 MCI的路径。初步筛查包括神经系统检查、简易精神状态检查和CT扫描。二次筛查包括容积MRI、统计SPECT、Rivermead行为记忆测试(RBMT)和脑电图(EEG)。符合MCI标准的患者在知情同意的情况下被招募到前瞻性研究中。高级检查包括脑脊液生物标志物(tau,磷酸化tau和Abeta),apoE表型,WAIS-R,WMS-R和PET扫描。MCI患者可能有早期AD或老年性tau蛋白病,我们招募他们通过乙酰胆碱酯酶抑制剂进行药物控制。初步总结如下:1. MCI包括除AD外的许多病例。2.适当的医疗干预可以预防,在某些情况下,逆转认知能力下降的进展。3.及早介入对维持生活质素十分有用,而有关个案现正不断累积。少
项目成果
期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Saito Y, Nakahara K, Yamanouchi H, Murayama S: "Severe Involvement of ambient gyros in dementia with grains."Journal of Neuropathology and Experimental Neurology. 61. 789-796 (2002)
Saito Y、Nakahara K、Yamanouchi H、Murayama S:“环境陀螺仪严重影响谷物痴呆。”神经病理学和实验神经病学杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Takeda, Y, Murayama, S. et al.: "Impaired motor coordination in mice lacking neural recognition molecule NB-3 of the contactin/ F3 subgroup."J Neurobiol. 56. 252-265 (2003)
Takeda, Y, Murayama, S. 等人:“缺乏 contactin/F3 亚组的神经识别分子 NB-3 的小鼠运动协调受损。”J Neurobiol。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K, Murayama S: "Niemann-Pick type C disease : accelerated neurofibrillary tangle formation and amyloid beta deposition associated with ApoE e4 homozygosity"Annals of Neurology. 52. 351-355 (2002)
Saito Y、Suzuki K、Nanba E、Yamamoto T、Ohno K、Murayama S:“Niemann-Pick C 型疾病:加速神经原纤维缠结形成和与 ApoE e4 纯合性相关的淀粉样蛋白沉积”《神经病学年鉴》。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Saito Y, Geyer A, Sasaki R, Kuzuhara S, Nanba E, Miyasaka T, Suzuki K, Murayama S: "Early onset, rapidly progressive familial tauopathy with R406W mutation"Neurology. 58. 811-813 (2002)
Saito Y、Geyer A、Sasaki R、Kuzuhara S、Nanba E、Miyasaka T、Suzuki K、Murayama S:“具有 R406W 突变的早发型、快速进展家族性 tau 病”神经病学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Saito Y, Suzuki K, Nanba E, Yamamoto T, Ohno K, Muravama S: "Niemann-Pick type C disease : accelerated neurofibrillary tangle formation and amyloid beta deposition associated with ApoE e4 homozygosity."Annals of Neurology. 52. 351-355 (2002)
Saito Y、Suzuki K、Nanba E、Yamamoto T、Ohno K、Muravama S:“Niemann-Pick C 型疾病:加速神经原纤维缠结形成和与 ApoE e4 纯合性相关的淀粉样蛋白沉积。”《神经病学年鉴》。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MURAYAMA Shigeo其他文献
MURAYAMA Shigeo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MURAYAMA Shigeo', 18)}}的其他基金
Analysis of protein propagation scheme of Lewy body- related alpha- synucleinopathy
路易体相关α-突触核蛋白病蛋白质增殖方案分析
- 批准号:
24300133 - 财政年份:2012
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Neuropathology of cognitive decline in Lewy body disease
路易体病认知能力下降的神经病理学
- 批准号:
20390248 - 财政年份:2008
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似国自然基金
骨髓基质干细胞移植对AD(Alzheimer disease)小鼠海马及额叶神经细胞死亡干预的实验研究
- 批准号:81301089
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Evaluation of the neurovascular unit in the setting of pathogenesis and treatment of autosomal dominant Alzheimer disease
常染色体显性阿尔茨海默病发病机制和治疗中神经血管单位的评估
- 批准号:
10572223 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Bayesian Statistical Learning for Robust and Generalizable Causal Inferences in Alzheimer Disease and Related Disorders Research
贝叶斯统计学习在阿尔茨海默病和相关疾病研究中进行稳健且可推广的因果推论
- 批准号:
10590913 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
用于治疗阿尔茨海默病和相关痴呆症的天然产物化合物的新组合
- 批准号:
10603708 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Enhancing Participation of Historically Minoritized Groups in Alzheimer Disease and Related Dementias Research
加强历史上少数群体对阿尔茨海默病和相关痴呆症研究的参与
- 批准号:
10752461 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Elucidating the Role of Endothelial Dysfunction in Alzheimer Disease: Towards A New Data-Driven Disease Model
阐明内皮功能障碍在阿尔茨海默病中的作用:建立新的数据驱动疾病模型
- 批准号:
10737969 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
A novel therapeutic approach for Alzheimer Disease (AD)
阿尔茨海默病(AD)的新治疗方法
- 批准号:
10740016 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Drugs repositioning to target TREM2 in Alzheimer disease
药物重新定位以治疗阿尔茨海默病中的 TREM2
- 批准号:
10639456 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
The Role of Adenosine Kinase in Mixed Diastolic Heart Failure and Alzheimer Disease
腺苷激酶在混合性舒张性心力衰竭和阿尔茨海默病中的作用
- 批准号:
10679989 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease
发现针对大脑 TNF-α 的治疗性纳米抗体用于治疗阿尔茨海默病
- 批准号:
10697218 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Deep-Learning-Augmented Quantitative Gradient Recalled Echo (DLA-qGRE) MRI for in vivo Clinical Evaluation of Brain Microstructural Neurodegeneration in Alzheimer Disease
深度学习增强定量梯度回忆回波 (DLA-qGRE) MRI 用于阿尔茨海默病脑微结构神经变性的体内临床评估
- 批准号:
10659833 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别: